Cowen reaffirmed their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report released on Monday morning.

Several other analysts have also recently issued reports on the stock. Roth Capital initiated coverage on shares of Syros Pharmaceuticals in a research note on Monday, October 23rd. They set a neutral rating and a $15.00 price objective for the company. Piper Jaffray Companies restated an overweight rating and issued a $30.00 price objective on shares of Syros Pharmaceuticals in a report on Tuesday, October 31st. ValuEngine lowered shares of Syros Pharmaceuticals from a hold rating to a sell rating in a report on Friday, September 22nd. Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, October 17th. Finally, JMP Securities upgraded shares of Syros Pharmaceuticals from a market perform rating to an outperform rating and set a $33.00 price objective on the stock in a report on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $26.14.

Shares of Syros Pharmaceuticals (NASDAQ SYRS) traded down $0.44 during trading on Monday, hitting $9.08. 663,800 shares of the company’s stock were exchanged, compared to its average volume of 132,761. Syros Pharmaceuticals has a 1-year low of $6.30 and a 1-year high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, hitting analysts’ consensus estimates of ($0.53). sell-side analysts expect that Syros Pharmaceuticals will post -2.1 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP acquired a new stake in shares of Syros Pharmaceuticals in the third quarter valued at about $240,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Syros Pharmaceuticals in the third quarter valued at about $149,000. Schwab Charles Investment Management Inc. raised its position in Syros Pharmaceuticals by 95.8% during the third quarter. Schwab Charles Investment Management Inc. now owns 41,709 shares of the company’s stock worth $614,000 after acquiring an additional 20,409 shares during the last quarter. Citadel Advisors LLC acquired a new position in Syros Pharmaceuticals during the third quarter worth about $975,000. Finally, Trexquant Investment LP acquired a new position in Syros Pharmaceuticals during the third quarter worth about $282,000. Institutional investors own 58.02% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Syros Pharmaceuticals (SYRS) Earns Buy Rating from Cowen” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/12/14/syros-pharmaceuticals-syrs-earns-buy-rating-from-cowen.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.